Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Solution for Peritoneal Dialysis
for Peritoneal Dialysis · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PDsol 12 | EXPERIMENTAL | Treatment with a peritoneal dialysis solution containing a low concentration of sodium. |
| Gambrosol trio 40 | ACTIVE_COMPARATOR | Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%) |
| Name | Type | Description |
|---|---|---|
| Solution for Peritoneal Dialysis | DRUG | Treatment with one bag per day during 6 months |
Inclusion Criteria: * Chronic renal failure * Stable patients on PD treatment * Treatment at the study site for at least three months * Treated in a CAPD program with a minimum of 3 bag exchanges with 6 or 7 days per week including at least one with duration of 4-6 hours, and at least one low stren...
Solution for Peritoneal Dialysis is an investigational small molecule therapy being developed by Fresenius Medical Care AG for chronic kidney failure. It is a low sodium peritoneal dialysis solution designed for patients with chronic kidney failure who are treated with peritoneal dialysis. It is also known as Solution for Peritoneal Dialysis.
Solution for Peritoneal Dialysis is being studied for use in patients with chronic kidney failure who are treated with peritoneal dialysis. The development program focuses on hypertensive patients receiving peritoneal dialysis, evaluating a low sodium peritoneal dialysis solution in that population.
Solution for Peritoneal Dialysis is developed by Fresenius Medical Care AG, which trades under the ticker FMS. Fresenius Medical Care AG is the sponsor of the clinical program evaluating this low sodium peritoneal dialysis solution in patients with chronic kidney failure.
Solution for Peritoneal Dialysis is in Phase 3 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 3 program has completed one trial, and no trials are currently active.
Solution for Peritoneal Dialysis has been evaluated in one completed Phase 3 trial, NCT00794326, titled Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD. The trial enrolled 140 patients with chronic kidney failure across Denmark, France, Germany, Sweden, and the United Kingdom.